Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a)

Lip GYH, Jones yAF. Lipoprotein(a) and vascular disease: thrombogenesis and atherogenesis. Q J Med 1995;88:529–539. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:905–910. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological significance. J Clin Invest 1990;85:1709–1715. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1953–1980. Bailleul S, Couderc R, Rossignol C et al. Lipoprotein(a) in childhood: relation with other atherosclerosis risk factors and family history of atherosclerosis. Clin Chem 1995;41:241–245. Heng CK, Saha N, Tay JS. Lack of association of apolipoprotein E polymorphism with plasma lp(a) levels in the Chinese. Clin Genet 1995;48:113–119. Lehtimäki T, Moilanen T, Viikari J et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990;31:487–495. Muros M, Rodrı́guez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis 1996;121:13–21. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23. Schaefer EJ, Lamon-Fava S, Johnson S et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Arterioscler Thromb 1994;14:1105–1113. de Knijff P, Kaptein A, Boomsma D, Princen HMG, Frants RR, Havekes LM. Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 1991;90:169–174. Horita K, Eto M, Saito M et al. Effects of apolipoprotein E polymorphism on plasma lipoprotein(a) levels. Artery 1993;20:324–336. Routi T, Rönnemaa T, Salo P et al. Effects of prospective, randomized cholesterol-lowering dietary intervention and apolipoprotein E phenotype on serum lipoprotein(a) concentrations of infants aged 7–24 mo. Am J Clin Nutr 1996;63:386–391. Tiret L, de Knijff P, Menzel H-J, Ehnholm C, Nicaud V, Havekes LM for the EARS group. Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. Arterioscler Thromb 1994;14:1617–1624. Ritter MM, Geiss HC, Richter WO, Schwandt P. Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism 1994;43:572–578. Bartens W, Rader DJ, Talley G, Brewer HB Jr. Lipoprotein(a) in patients with hyperlipidaemia. Eur J Clin Invest 1995;25:647–653. Lind H, Nilsson, Holthuis N, Lindholm L. Non-obese men with high lipoprotein(a) values—a cardiovascular risk group different from those with the metabolic syndrome? Scand J Clin Lab Invest 1994;54:177–183. Walek T, von Eckardstein A, Schulte H, Assmann G. Effect of hypertriglyceridaemia on lipoprotein(a) serum concentrations. Eur J Clin Invest 1995;25:311–316. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta-analysis. J Lipid Res 1992;33:447–454. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985;37:268–285. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502. Geiss HC, Ritter MM, Richter WO, Schwandt P. Determination of apolipoprotein(a) isoforms by sodium dodecyl sulfate-polyacrylamide electrophoresis and immunoblotting. Anal Biochem 1993;213:168–169 Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes—inheritance and relation to lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458–465. Menzel H-J, Utermann G. Apolipoprotein E phenotyping from serum by Western blotting. Electrophoresis 1986;7:492–495. Menzel H-J, Kladetzky R-G, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983;3:310–315. Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D. Heterogeneity of human lipoprotein lp(a): cytochemical and biochemical studies on the interaction of two lp(a) species with the LDL receptor. J Lipid Res 1990;31:429–441. Kostner GM. Interaction of lp(a) and of apo(a) with liver cells. Arterioscler Thromb 1993;13:1101–1109. Steyrer E, Kostner GM. Interaction of lipoprotein lp(a) with the B/E receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors. J Lipid Res 1990;31:1247–1253. Mbewu AD, Bhatnagar D, Durrington PN et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991;11:940–946. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentrations and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl J Med 1990;322:1494–1499. Wiklund O, Angelin B, Olofsson S-O et al. Apolipoprotein(a) and ischemic heart disease in familial hypercholesterolemia. Lancet 1990;335:1360–1363. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year treatment with pravastatin, an HMG-CoA Reductase inhibitor, on lipoprotein(a). J Clin Pharmacol 1993;33:574–580. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol levels without reducing lp(a) levels. Circulation 1989;80:1313–1319. März W, Grutzmacher P, Paul D, Siekmeier R, Schoeppe W, Gross W. Effects of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia. Int J Clin Pharmacol Ther 1994;32:92–97. Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D. Serum lipoprotein(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 1988;66:462–463. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein lp(a). Atherosclerosis 1982;44:61–71. Rader DJ, Mann WA, Cain W et al. The low density lipoprotein receptor is not required for normal catabolism of lp(a) in humans. J Clin Invest 1995;95:1403–1408 März W, Beckmann A, Scharnagl H et al. Heterogeneous lipoprotein(a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/a2-macroglobulin receptor. FEBS Lett 1993;325:271–275. Bard J-M, Delattre-Lestavel S, Clavey V et al. Isolation and characterization of two sub-species of lp(a), one containing apoE and one free of apoE. Biochim Biophys Acta 1992;1127:124–130. Blanco-Vaca F, Gaubatz JW, Bren N, Kottke BA, Morrisett JD, Guevara J Jr. Identification and quantification of apolipoproteins in addition to apo(a) and apo B-100 in human lipoprotein(a). Chem Phys Lipids 1994;67/68:35–42. Kamboh MI, Evans RW, Aston CE. Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphism on plasma quantitative risk factors for coronary heart disease in American Black women. Atherosclerosis 1995;117:73–81. Sandholzer C, Hallman DM, Saha N et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607–614. Lindahl G, Mailly F, Humphries S, Seed M. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolemia: implication for lipoprotein(a) metabolism. Clin Investig 1994;72:631–638. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992;90:220–230. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52–60. DeMeester CA, Bu X, Gray RJ, Lusis AJ, Rotter JI. Genetic variation in lipoprotein(a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein(a) gene locus. Am J Hum Genet 1995;56:287–293. Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis 1995;113:79–89.